Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 109

1.

Estimating survival for renal cell carcinoma patients with brain metastases: an update of the Renal Graded Prognostic Assessment tool.

Sperduto PW, Deegan BJ, Li J, Jethwa KR, Brown PD, Lockney N, Beal K, Rana NG, Attia A, Tseng CL, Sahgal A, Shanley R, Sperduto WA, Lou E, Zahra A, Buatti JM, Yu JB, Chiang V, Molitoris JK, Masucci L, Roberge D, Shi DD, Shih HA, Olson A, Kirkpatrick JP, Braunstein S, Sneed P, Mehta MP.

Neuro Oncol. 2018 Nov 12;20(12):1652-1660. doi: 10.1093/neuonc/noy099.

PMID:
30418657
2.

Marked Response of a Hypermutated ACTH-Secreting Pituitary Carcinoma to Ipilimumab and Nivolumab.

Lin AL, Jonsson P, Tabar V, Yang TJ, Cuaron J, Beal K, Cohen M, Postow M, Rosenblum M, Shia J, DeAngelis LM, Taylor BS, Young RJ, Geer EB.

J Clin Endocrinol Metab. 2018 Oct 1;103(10):3925-3930. doi: 10.1210/jc.2018-01347.

PMID:
30085142
3.

Effect of Targeted Therapies on Prognostic Factors, Patterns of Care, and Survival in Patients With Renal Cell Carcinoma and Brain Metastases.

Sperduto PW, Deegan BJ, Li J, Jethwa KR, Brown PD, Lockney N, Beal K, Rana NG, Attia A, Tseng CL, Sahgal A, Shanley R, Sperduto WA, Lou E, Zahra A, Buatti JM, Yu JB, Chiang V, Molitoris JK, Masucci L, Roberge D, Shi DD, Shih HA, Olson A, Kirkpatrick JP, Braunstein S, Sneed P, Mehta MP.

Int J Radiat Oncol Biol Phys. 2018 Jul 15;101(4):845-853. doi: 10.1016/j.ijrobp.2018.04.006. Epub 2018 Apr 12.

PMID:
29976497
4.

Phosphatidylinositol-3-Kinase Mutations Are Associated With Increased Local Failure in Brain Metastases Treated With Radiation.

Lockney NA, Wang DG, Pei X, Goldman DA, Zhang Z, Lin A, Chan TA, Yamada Y, Beal K, Yang TJ.

Int J Radiat Oncol Biol Phys. 2018 Jul 15;101(4):833-844. doi: 10.1016/j.ijrobp.2018.03.032. Epub 2018 Mar 29.

PMID:
29976496
5.

Analytical subcloning of a clonal cell line demonstrates cellular heterogeneity that does not impact process consistency or robustness.

Scarcelli JJ, Hone M, Beal K, Ortega A, Figueroa B, Starkey JA, Anderson K.

Biotechnol Prog. 2018 May;34(3):602-612. doi: 10.1002/btpr.2646. Epub 2018 Jul 1.

6.

Multicenter Phase IB Trial of Carboxyamidotriazole Orotate and Temozolomide for Recurrent and Newly Diagnosed Glioblastoma and Other Anaplastic Gliomas.

Omuro A, Beal K, McNeill K, Young RJ, Thomas A, Lin X, Terziev R, Kaley TJ, DeAngelis LM, Daras M, Gavrilovic IT, Mellinghoff I, Diamond EL, McKeown A, Manne M, Caterfino A, Patel K, Bavisotto L, Gorman G, Lamson M, Gutin P, Tabar V, Chakravarty D, Chan TA, Brennan CW, Garrett-Mayer E, Karmali RA, Pentsova E.

J Clin Oncol. 2018 Jun 10;36(17):1702-1709. doi: 10.1200/JCO.2017.76.9992. Epub 2018 Apr 23.

PMID:
29683790
7.

Brain Metastases in Pancreatic Ductal Adenocarcinoma: Assessment of Molecular Genotype-Phenotype Features-An Entity With an Increasing Incidence?

Jordan EJ, Lowery MA, Basturk O, Allen PJ, Yu KH, Tabar V, Beal K, Reidy DL, Yamada Y, Janjigian Y, Abou-Alfa GK, O'Reilly EM.

Clin Colorectal Cancer. 2018 Jun;17(2):e315-e321. doi: 10.1016/j.clcc.2018.01.009. Epub 2018 Feb 7.

PMID:
29496399
8.

Institutional experience with SRS VMAT planning for multiple cranial metastases.

Ballangrud Å, Kuo LC, Happersett L, Lim SB, Beal K, Yamada Y, Hunt M, Mechalakos J.

J Appl Clin Med Phys. 2018 Mar;19(2):176-183. doi: 10.1002/acm2.12284. Epub 2018 Feb 23.

9.

Characteristics and Prognostic Factors for Patients With HER2-overexpressing Breast Cancer and Brain Metastases in the Era of HER2-targeted Therapy: An Argument for Earlier Detection.

Morikawa A, Wang R, Patil S, Diab A, Yang J, Hudis CA, McArthur HL, Beal K, Seidman AD.

Clin Breast Cancer. 2018 Oct;18(5):353-361. doi: 10.1016/j.clbc.2017.12.009. Epub 2017 Dec 21.

PMID:
29337140
10.

Trends in newborn umbilical cord care practices in Sokoto and Bauchi States of Nigeria: the where, who, how, what and the ubiquitous role of traditional birth attendants: a lot quality assurance sampling survey.

Abegunde D, Orobaton N, Beal K, Bassi A, Bamidele M, Akomolafe T, Ohanyido F, Umar-Farouk O, Danladi S.

BMC Pregnancy Childbirth. 2017 Nov 9;17(1):368. doi: 10.1186/s12884-017-1551-x.

11.

Estimating Survival in Melanoma Patients With Brain Metastases: An Update of the Graded Prognostic Assessment for Melanoma Using Molecular Markers (Melanoma-molGPA).

Sperduto PW, Jiang W, Brown PD, Braunstein S, Sneed P, Wattson DA, Shih HA, Bangdiwala A, Shanley R, Lockney NA, Beal K, Lou E, Amatruda T, Sperduto WA, Kirkpatrick JP, Yeh N, Gaspar LE, Molitoris JK, Masucci L, Roberge D, Yu J, Chiang V, Mehta M.

Int J Radiat Oncol Biol Phys. 2017 Nov 15;99(4):812-816. doi: 10.1016/j.ijrobp.2017.06.2454.

PMID:
29063850
12.

Melanoma brain metastases treated with stereotactic radiosurgery and concurrent pembrolizumab display marked regression; efficacy and safety of combined treatment.

Anderson ES, Postow MA, Wolchok JD, Young RJ, Ballangrud Å, Chan TA, Yamada Y, Beal K.

J Immunother Cancer. 2017 Oct 17;5(1):76. doi: 10.1186/s40425-017-0282-x.

13.

Long-term outcomes of adult medulloblastoma patients treated with radiotherapy.

De B, Beal K, De Braganca KC, Souweidane MM, Dunkel IJ, Khakoo Y, Gilheeney SW, DeAngelis LM, Menzel P, Patel SH, Wolden SL.

J Neurooncol. 2018 Jan;136(1):95-104. doi: 10.1007/s11060-017-2627-1. Epub 2017 Oct 10.

PMID:
29019042
14.

Early posttreatment assessment of MRI perfusion biomarkers can predict long-term response of lung cancer brain metastases to stereotactic radiosurgery.

Taunk NK, Oh JH, Shukla-Dave A, Beal K, Vachha B, Holodny A, Hatzoglou V.

Neuro Oncol. 2018 Mar 27;20(4):567-575. doi: 10.1093/neuonc/nox159.

PMID:
29016814
15.

Modernizing Clinical Trial Eligibility Criteria: Recommendations of the American Society of Clinical Oncology-Friends of Cancer Research Brain Metastases Working Group.

Lin NU, Prowell T, Tan AR, Kozak M, Rosen O, Amiri-Kordestani L, White J, Sul J, Perkins L, Beal K, Gaynor R, Kim ES.

J Clin Oncol. 2017 Nov 20;35(33):3760-3773. doi: 10.1200/JCO.2017.74.0761. Epub 2017 Oct 2.

PMID:
28968165
16.

Twice weekly pulse and daily continuous-dose erlotinib as initial treatment for patients with epidermal growth factor receptor-mutant lung cancers and brain metastases.

Arbour KC, Kris MG, Riely GJ, Ni A, Beal K, Daras M, Hayes SA, Young RJ, Rodriguez CR, Ahn L, Pao W, Yu HA.

Cancer. 2018 Jan 1;124(1):105-109. doi: 10.1002/cncr.30990. Epub 2017 Sep 21.

PMID:
28940498
17.

Multicenter, Phase 1, Dose Escalation Study of Hypofractionated Stereotactic Radiation Therapy With Bevacizumab for Recurrent Glioblastoma and Anaplastic Astrocytoma.

Clarke J, Neil E, Terziev R, Gutin P, Barani I, Kaley T, Lassman AB, Chan TA, Yamada J, DeAngelis L, Ballangrud A, Young R, Panageas KS, Beal K, Omuro A.

Int J Radiat Oncol Biol Phys. 2017 Nov 15;99(4):797-804. doi: 10.1016/j.ijrobp.2017.06.2466. Epub 2017 Jun 30.

PMID:
28870792
18.

The Prognostic Value of BRAF, C-KIT, and NRAS Mutations in Melanoma Patients With Brain Metastases.

Sperduto PW, Jiang W, Brown PD, Braunstein S, Sneed P, Wattson DA, Shih HA, Bangdiwala A, Shanley R, Lockney NA, Beal K, Lou E, Amatruda T, Sperduto WA, Kirkpatrick JP, Yeh N, Gaspar LE, Molitoris JK, Masucci L, Roberge D, Yu J, Chiang V, Mehta M.

Int J Radiat Oncol Biol Phys. 2017 Aug 1;98(5):1069-1077. doi: 10.1016/j.ijrobp.2017.03.030. Epub 2017 Mar 29.

PMID:
28721890
19.

Clinical outcomes of patients with limited brain metastases treated with hypofractionated (5×6Gy) conformal radiotherapy.

Lockney NA, Wang DG, Gutin PH, Brennan C, Tabar V, Ballangrud A, Pei X, Chan TA, Yamada Y, Yang TJ, Beal K.

Radiother Oncol. 2017 May;123(2):203-208. doi: 10.1016/j.radonc.2017.03.018. Epub 2017 Apr 5.

20.

The radiosurgery fractionation quandary: single fraction or hypofractionation?

Kirkpatrick JP, Soltys SG, Lo SS, Beal K, Shrieve DC, Brown PD.

Neuro Oncol. 2017 Apr 1;19(suppl_2):ii38-ii49. doi: 10.1093/neuonc/now301.

Supplemental Content

Loading ...
Support Center